Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis.
Currently the only Food and Drug Administration-approved treatment for children with chronic hepatitis C virus is pegylated interferon with ribavirin, which is associated with significant adverse effects and low sustained virologic response rates. In this report, we discuss the use of ledipasvir/sofosbuvir to treat an adolescent with cirrhosis secondary to chronic hepatitis C virus.